Audit: QRS - Xylitol for Health & Longevity
Audit conducted on 11/08/2026 09:25 using AI4L / Opus 5
Summary
| Items | Count |
|---|---|
| Total | 93 |
| Passed | 83 |
| Failed | 0 |
| N/A | 10 |
| Pass Rate | 100.00% |
- Total = Passed + Failed + N/A
- Pass Rate = Passed / (Passed + Failed) × 100
- N/A items are excluded from the pass rate calculation
1. General Rules
| # | Description | Result | Comments |
|---|---|---|---|
| 1.1 | Every claim, magnitude, label, recommendation, and statement in the QRS is literally supported by content in the source ER. | 🟢 | All protocol cells, tier lists, gate items, markers, targets and qualitative items trace to ER Therapeutic Protocol, Expected Benefits, Potential Risks & Side Effects, Key Interactions & Contraindications, Practical Considerations and Monitoring Protocol & Defining Success. |
| 1.2 | Where the ER uses cautious phrasing (“not formally studied”, “None documented in human trials to date”, “theoretical concern”, “data are limited”), the QRS uses the same phrasing. | 🟢 | ”; theoretical” retained on the antiplatelet-supplement interaction (ER: “Caution, theoretical.”); “Association with major adverse cardiovascular events” and “A disputed link … is unresolved” preserve the ER’s conflicted framing. |
| 1.3 | The QRS never strengthens an ER claim (e.g., “not formally studied” → “not required”) or softens one (e.g., “do not use during pregnancy” → “use with caution during pregnancy”). | 🟢 | Contraindications remain avoidance statements; the cardiovascular signal remains an association; “at extreme or intravenous doses” is retained on the low-tier risk so it is not generalized to dietary intake. |
| 1.4 | The QRS does not relabel an ER fact under a different decision category. A “Benefit-Modifying Factor” from ER section is not surfaced as a “Caution”; a “Risk-Modifying Factor” is not surfaced as a “Side Effect”; etc. | 🟢 | Contraindications come from the ER’s “Populations who should avoid Xylitol” list; Key Interactions from the ER’s interaction bullets; tiers map 1:1 to the ER’s own High/Medium/Low/Speculative tiers. |
| 1.5 | PubMed IDs, study citations, expert names, clinical trial identifiers (NCT*), and brand names appear in the QRS only if they appear in the source ER for the same fact. | 🟢 | The QRS contains no PMIDs, citations, expert names, NCT identifiers or brand names. |
| 1.6 | The QRS does not introduce new attributions. | 🟢 | No attributions of any kind appear in the QRS. |
2. Focus, Tone & Audience
| # | Description | Result | Comments |
|---|---|---|---|
| 2.1 | The QRS follows the tone of the ER, which is determined by the ER’s own language, phrasing, and framing. | 🟢 | Neutral, evidence-first register matching the ER; conflicted findings are carried over as unresolved rather than settled. |
| 2.2 | The tone of the QRS is simultaneously expert, accessible, objective, and data-driven, but also empowering and encouraging | 🟢 | Quantified protocol targets, biomarker ranges and cadence give an actionable, data-driven sheet without exhortation. |
| 2.3 | The QRS reads as a trusted, knowledgeable guide rather than a prescriptive doctor | 🟢 | Protocol cells are stated descriptively (“Gum chewed after meals and snacks, or a lozenge dissolved slowly”), not as commands. |
| 2.4 | The QRS avoids language that implies medical or clinical advice | 🟢 | No directive verbs; the footer disclaimer remains the template’s. |
| 2.5 | The QRS “presents information” instead of “providing guidance”, “recommending”, or “advising” | 🟢 | No instances of “recommend”, “advise”, “should” or equivalent in the QRS voice. |
| 2.6 | The QRS never addresses “the reader” directly — it presents evidence, not guidance | 🟢 | No second-person pronouns anywhere in the body. |
| 2.7 | The QRS is written in plain language, avoiding unnecessary medical jargon | 🟢 | Technical terms are confined to the Monitoring table, where they are the ER’s own biomarker names and unavoidable. |
| 2.8 | Information is presented in a concise and very compact manner | 🟢 | Every gate, tier and protocol entry is reduced to the key fact; no trailing rationale anywhere. |
| 2.9 | It DOES NOT address the reader directly | 🟢 | Confirmed by full-text scan of the rendered body. |
| 2.10 | The target audience is health- and longevity-oriented adults who are risk-aware, proactive, and actively seeking to optimize health or apply the intervention under review. | 🟢 | Content assumes a reader executing a titrated dental protocol and tracking eight biomarkers. |
| 2.11 | The target audience is willing to employ lifestyle and behavioral changes as well as follow protocols that may be inconvenient, costly, or require effort. | 🟢 | 3–5 daily exposures, 5-minute chewing, and radiographic follow-up all assume a high-effort reader. |
| 2.12 | The document is NOT written for the general population, who are unwilling to employ lifestyle and behavioral changes or follow protocols that may be inconvenient, costly, or require effort. | 🟢 | Aggregometry, unstimulated salivary flow rate and Silness–Löe plaque index are not general-population content. |
| 2.13 | Framing, takeaways, and risk/benefit weighting throughout the document reflect this audience, including where an intervention’s signal for the average person differs from its signal for this audience. | 🟢 | The unresolved cardiovascular signal is surfaced as a medium-tier risk, a 90-day post-event contraindication, and a platelet-function marker — the weighting a risk-aware reader needs. |
| 2.14 | The document’s own voice frames usage in longevity terms, not “anti-aging” (e.g., “anti-aging clinics”, “anti-aging community”, “anti-aging medicine”). Proper names that contain “anti-aging” (e.g., “American Academy of Anti-Aging Medicine”) are quoted verbatim. | 🟢 | The string “anti-aging” does not occur in the QRS. |
| 2.15 | The document’s own voice uses formal clinical and scientific terminology, not colloquial or consumer-grade language (e.g., “oral medication” not “pill(s)”; “injection” not “shot”; “adverse event” not “bad reaction”). Direct quotes from sources are exempt. | 🟢 | “Osmotic diarrhea”, “acute coronary syndrome”, “small intestinal bacterial overgrowth”, “unstimulated salivary flow rate”; the informal-sounding qualitative items are the ER’s own verbatim wording. |
3. Template Integrity
| # | Description | Result | Comments |
|---|---|---|---|
| 3.1 | The following labels and headings on the QRS are fixed and not modified: Card and section headings: “Protocol”, “Time to effect”, “Benefits”, “Risk & Side Effects”, “Monitoring”, “Qualitative Assessment”; Gate headings: “Contraindications”, “Key Interactions”; Tier labels: “High”, “Medium”, “Low”, “Speculative”; Table column headers in Monitoring: “Marker”, “Target”, “Why” | 🟢 | All fourteen fixed strings verified byte-identical to [qrs_template] (QRS lines 440, 477, 519, 539, 550, 570, 589, 593–595, 697). |
| 3.2 | All “…” from the [qrs_template] are present in the the QRS. | 🟢 | All 34 named template spans present; the repeatable marker_#_* and qualitative_item_# spans are instantiated 8× and 5× respectively. |
| 3.3 | Spans that are not addressed in a checklist item are left unchanged | 🟢 | <span website="evidence_review">, <span website="audit"> and <span website="full_review"> are untouched; a structural diff against the template shows changes only inside data-qrs-var spans, the metadata block and <title>. |
4. Formatting
| # | Description | Result | Comments |
|---|---|---|---|
| 4.1 | When the source ER section is empty, the QRS uses the ER’s own empty-state phrasing verbatim. Typical phrasings are “None documented in human trials to date” and “Not formally studied” | N/A | No source ER section mapped by this QRS is empty. |
| 4.2 | Where the ER presents a bulleted item as “Label: content”, the QRS uses the ER’s bold label verbatim as the cell or row label. | 🟢 | Protocol labels (“Standard dental dose”, “Chewing duration”, “Best time of day”) and all eight Key Interaction labels reproduce the ER’s bold labels verbatim. |
| 4.3 | Labels are not paraphrased, abbreviated, or invented. | 🟢 | Every label with an ER counterpart is verbatim; the Time-to-effect cell labels sit under a single ER bullet that supplies no per-aspect labels. |
| 4.4 | The QRS DOES NOT use emoji indicators (no 🟩, 🟥, 🟨, etc.). Color and emphasis are conveyed through CSS and bold labels. | 🟢 | Character scan of the file returns no emoji code points; the ER’s 🟩/🟥/🟨/⚠️ markers were correctly dropped. |
| 4.5 | The QRS is designed to render on one A4 page. Any section that has more content in the ER than fits the per-section budget is condensed by the LLM, not extended onto a second page. | 🟢 | Every section is condensed to bare headings/labels with all trailing rationale stripped; remaining volume is the completeness minimum required by 9.2, 14.2 and 15.2. |
5. Metadata
| # | Description | Result | Comments |
|---|---|---|---|
| 5.1 | The metadata is placed inside a single HTML comment that is the first element after “<!doctype html>” and before any other comment, head, or body content. | 🟢 | Single comment at lines 2–14, immediately after <!doctype html> on line 1. |
| 5.2 | Inside that HTML comment the YAML block is delimited by a line “—” opening and a line “—” closing. Text before the opening “—” is permitted but is not parsed as YAML. | 🟢 | Opening --- at line 3, closing --- at line 13; the preceding “QRS — Metadata” caption sits before the opening delimiter. |
| 5.3 | The metadata is not visible in any rendered view of the QRS and is not surfaced by any other element on the sheet. | 🟢 | Enclosed in an HTML comment; no metadata value is repeated in the header, footer or body. |
| 5.4 | All frontmatter values are trimmed: no leading or trailing whitespace, no surrounding quotes unless the value contains a colon, bracket, or leading special character that requires YAML quoting. | 🟢 | Only duration: "00:02" is quoted, and it contains a colon; all other values are bare and trimmed. |
| 5.5 | The filename of the source ER is stated as “er_filename: [er_filename]” | 🟢 | Line 4: er_filename: xylitol_2026-0811-0654_Opus_ER.md. |
| 5.6 | Version of the QRS.md file used to create the document is stated as “qrs_prompt_version: [Version of QRS.md]” | 🟢 | Line 5: qrs_prompt_version: 26.7.02, matching the QRS.md version badge. |
| 5.7 | Creation date and time of the document is stated as “qrs_creation_date: [YYYY-MMDD-HHMM]” (e.g., 2026-0501-1430) | 🟢 | Line 6: qrs_creation_date: 2026-0811-0905. |
| 5.8 | The nickname of the AI used to create the document is stated as “qrs_creator_ai_nickname: [qrs_creator_ai_nickname]” | 🟢 | Line 7: qrs_creator_ai_nickname: Opus. |
| 5.9 | The nickname of the AI is just a single word model name without version, etc. (e.g., Opus, Sonnet, Grok, Gemini, ChatGPT) | 🟢 | “Opus” — single word, no version or qualifier. |
| 5.10 | The full name of the AI used to create the document is stated as “qrs_creator_ai_fullname: [qrs_creator_ai_fullname]” | 🟢 | Line 8: qrs_creator_ai_fullname: Opus 5. |
| 5.11 | The full name of the AI consists of the [qrs_creator_ai_nickname] and the model version number and no additional qualifier (e.g., Opus 4.6, Sonnet 3.2, Grok 4.5, Gemini 3.1, ChatGPT 5.4) | 🟢 | “Opus 5” = nickname + version, no qualifier. |
| 5.12 | The filename of the document is stated as “qrs_filename: [filename of this document]” | 🟢 | Line 9: qrs_filename: xylitol_2026-0811-0654_Opus_QRS.html, matching the file on disk. |
| 5.13 | All frontmatter values are trimmed: no leading or trailing whitespace, no surrounding quotes unless the value contains a colon, bracket, or leading special character that requires YAML quoting. | 🟢 | Re-verified across all nine keys including git_user: evipedia-2 and git_issue: 5037. |
6. Page Title & Header
| # | Description | Result | Comments |
|---|---|---|---|
| 6.1 | [page_title] is set to the [canonical_topic] of the ER frontmatter followed by “ - Quick Reference Sheet” (e.g., “Intervention - Quick Reference Sheet”). The [canonical_topic] is HTML-entity-encoded as needed (e.g., & for &) |
🟢 | Line 22: Xylitol for Health & Longevity - Quick Reference Sheet, matching ER canonical_topic with & encoded. |
| 6.2 | [header_topic] is set to the [canonical_topic] of the ER frontmatter, with HTML entities encoded as needed (e.g., & for &) |
🟢 | Line 417: Xylitol for Health & Longevity. |
| 6.3 | [header_subline_date] is set to [qrs_creation_date reformatted as MM/DD/YYYY] | 🟢 | Line 421: 08/11/2026, correct reformatting of 2026-0811. |
| 6.4 | [header_subline_model] is set to [qrs_creator_ai_fullname] | 🟢 | Line 425: Opus 5, matching the frontmatter value. |
| 6.5 | No additional header content appears: no badge, version stamp, AKA / alternate names line, source-AI attribution, audit date, or QRS variant marker. | 🟢 | Header markup is byte-identical to the template apart from the two variable spans; the ER’s “Also known as” line was not carried over. |
7. At-A-Glance Section
| # | Description | Result | Comments |
|---|---|---|---|
| 7.1 | [at_a_glance] is dense, execution-oriented summary of the ER Conclusion section |
🟢 | Compresses all three Conclusion paragraphs into the decision-relevant core: dental effect, digestive ceiling, unresolved cardiovascular signal, canine lethality. |
| 7.2 | [at_a_glance] is no longer than 60 words | 🟢 | Programmatic word count: exactly 60. |
| 7.3 | Every fact in [at_a_glance] is supported by a distinct passage in the ER. | 🟢 | Each clause maps to a distinct Conclusion sentence (ER lines 464, 466). |
| 7.4 | It DOES NOT use acronyms or technical classifications that require specialist knowledge, uses plain-language terms instead | 🟢 | No acronyms; “tooth decay”, “blood sugar”, “heart attacks and strokes”, “diarrhea and bloating” are all lay terms. |
| 7.5 | It DOES NOT cite specific trials (names, years, sample sizes, p-values) | 🟢 | No trial names, years, sample sizes or p-values. |
| 7.6 | It DOES NOT cite effect sizes, relative risks, or statistical results | 🟢 | No hazard ratios, confidence intervals or effect sizes; the cardiovascular finding is stated only as a “disputed link”. |
8. Contraindications
| # | Description | Result | Comments |
|---|---|---|---|
| 8.1 | The section is derived from the ER Key Interactions & Contraindications section |
🟢 | All four items come from the “Populations who should avoid Xylitol” list (ER lines 313–318). |
| 8.2 | [stop_items] represent the Contraindications from the ER | 🟢 | All four ER avoidance populations present, in ER order, none added. |
| 8.3 | Individual [stop_items] are formatted as <li></li> | 🟢 | Four <li> elements inside the stop_items span (QRS lines 542–545). |
| 8.4 | Items are as concise as possible. No trailing explanations, no elaborations, no mechanistic rationale, no attributions, no citations, no study details. No content after an em-dash, en-dash, or hyphen-dash (e.g., “— dose reduction required”, “— reduced efficacy”) — these trailing clauses are stripped. Just the key fact. | 🟢 | The canine “— the canine threshold is about 0.1 g/kg body weight” clause and the “as a precaution while the platelet question is unresolved” rationale are both stripped; the redundant “People with” prefix is dropped. |
| 8.5 | Parenthetical qualifiers from the ER bullet — time windows, severity classes, threshold values, clinical staging — ARE preserved as part of the item, kept as concise as possible (shortened or trimmed where needed to fit the one-page budget, but never dropped entirely). | 🟢 | “during active symptom flares”, “active inflammatory bowel disease flare”, “ongoing infectious diarrhea” and the “Within 90 days” time window are all preserved. |
| 8.6 | When the ER uses ranking notation inside parens (e.g., “>” for severity ordering) that depends on an explanatory phrase to interpret, normalize the items to a plain comma-separated list rather than carrying through the bare symbol. | N/A | The ER’s avoidance list uses no ranking notation inside parentheses. |
| 8.7 | The section is left empty ONLY IF the ER’s Key Interactions & Contraindications section identifies no population, condition, or scenario for which the intervention should be avoided, deferred, or used only under specialist supervision. |
🟢 | The ER names four such populations and the section is correctly populated rather than empty. |
| 8.8 | If the section is left empty, an HTML comment inside the [stop_items] span records the ER basis for the absence, naming or quoting the ER text relied on. E.g. <!-- empty: ER names no population that should avoid the intervention --> |
N/A | The section is not empty. |
9. Key Interactions
| # | Description | Result | Comments |
|---|---|---|---|
| 9.1 | The section is derived from the ER Key Interactions & Contraindications section |
🟢 | All eight items come from the ER’s interaction bullets (ER lines 297–311). |
| 9.2 | [caution_items] represent the Key Interactions from the ER, excluding any that are already listed as Contraindications | 🟢 | All eight ER interaction bullets present in ER order; none duplicates a contraindication. |
| 9.3 | Individual [caution_items] are formatted as <li></li> | 🟢 | Eight <li> elements inside the caution_items span (QRS lines 553–560). |
| 9.4 | Items are as concise as possible. No trailing explanations, no elaborations, no mechanistic rationale, no attributions, no citations, no study details. No content after an em-dash, en-dash, or hyphen-dash (e.g., “— dose reduction required”, “— reduced efficacy”) — these trailing clauses are stripped. Just the key fact. | 🟢 | Every “Caution.”/”Monitor.” sentence, mechanism and mitigation instruction is stripped; only the ER’s bold label survives. |
| 9.5 | Parenthetical qualifiers from the ER bullet — example drug lists, time windows, severity classes, threshold values, clinical staging — ARE preserved as part of the item, kept as concise as possible (shortened or trimmed where needed to fit the one-page budget, but never dropped entirely). | 🟢 | All five parenthetical drug/supplement/polyol lists are carried through in full, and the “theoretical” qualifier is retained on the antiplatelet-supplement item. |
| 9.6 | When the ER uses ranking notation inside parens (e.g., “>” for severity ordering) that depends on an explanatory phrase to interpret, normalize the items to a plain comma-separated list rather than carrying through the bare symbol. | N/A | The ER’s parentheses contain plain comma-separated lists only; no ranking notation is used. |
| 9.7 | The section is left empty ONLY IF the ER’s Key Interactions & Contraindications section identifies no interaction, additive effect, or exposure that changes how the intervention is used. |
🟢 | The ER names eight such interactions and the section is correctly populated rather than empty. |
| 9.8 | If the section is left empty, an HTML comment inside the [caution_items] span records the ER basis for the absence, naming or quoting the ER text relied on. E.g. <!-- empty: ER names no interaction that changes how the intervention is used --> |
N/A | The section is not empty. |
10. Protocol
| # | Description | Result | Comments |
|---|---|---|---|
| 10.1 | The section is derived from the ER Protocol section |
🟢 | All three cells derive from the ER Therapeutic Protocol bullets (ER lines 340, 344, 350). |
| 10.2 | The three sets of [action] items cover the three most important actionable implementation aspects from the ER Protocol section |
🟢 | Dose, contact duration and timing — the three levers the ER identifies; the ER’s frequency bullet is folded into the dose cell’s sub-line. |
| 10.3 | If less that three distinct actionable implementation aspects are mentioned in the ER the unused sets are left empty and made invisible, not filled with placeholder text or empty-state phrasing. | N/A | The ER supplies well over three actionable aspects; all three sets are used. |
| 10.4 | All used [action_#label], [action#value], [action#_sub] items are filled with meaningful content derived from the ER Protocol section. |
🟢 | Nine of nine variables populated; e.g. “6–10 g daily” / “Divided across 3–5 exposures; bacterial suppression plateaus near 6.9 g” matches ER line 340. |
11. Time to Effect
| # | Description | Result | Comments |
|---|---|---|---|
| 11.1 | The three sets of [time] items cover the three most important time-to-effect aspects from the ER | 🟢 | Plaque/bacteria 2–6 weeks and lesions 12–36 months from ER line 395; gut adaptation 2–4 weeks from ER line 245. |
| 11.2 | The sets are picked and ordered by the magnitude of the related benefit | 🟢 | High-tier plaque/bacteria first, medium-tier caries second, the tolerance timeline (no associated benefit tier) last. |
| 11.3 | If less that three distinct time-to-effect aspects are mentioned in the ER the unused sets are left empty and made invisible, not filled with placeholder text or empty-state phrasing. | N/A | The ER supplies at least three distinct time-to-effect aspects; all three sets are used. |
| 11.4 | All used [time_#label], [time#value], [time#_sub] items are filled with meaningful content derived from the ER. | 🟢 | Nine of nine variables populated with ER-sourced timings and explanations. |
| 11.5 | If the ER does not provide any information on time to effect, the section is removed completely from the Protocol Panel |
N/A | The ER provides an explicit “Time to effect” bullet, so the section is correctly retained. |
12. Benefits
| # | Description | Result | Comments |
|---|---|---|---|
| 12.1 | The section is derived from the ER Expected Benefits section |
🟢 | All ten entries are the ER’s own Expected Benefits sub-headings. |
| 12.2 | Key variables are [benefits_high], [benefits_medium], [benefits_low], [benefits_speculative] | 🟢 | All four spans present and populated (QRS lines 521–532), matching the ER’s 2 / 4 / 2 / 2 tier distribution. |
| 12.3 | Items are as concise as possible. No explanations, no elaborations, no effect sizes, no qualifiers, no attributions, no citations, no study details, no mechanistic explanations, etc. Just the key fact. | 🟢 | Only the ER sub-headings survive; every Magnitude: line, confidence interval and mechanism paragraph is dropped. |
| 12.4 | Parenthetical content — including effect sizes, sample notes, mechanistic hints, and example studies — is stripped, NOT preserved. | 🟢 | No parentheses appear in any benefits item; the ER’s “⚠️ Conflicted” marker on caries incidence is also dropped. |
| 12.5 | If no items of a specific sub-section (high, medium, low, speculative) are present the respective <SPAN> is set to “display=none”, not filled with “None documented in human trials to date” or similar empty-state phrasing. |
N/A | All four ER benefit tiers contain items, so no span needs hiding. |
13. Risks
| # | Description | Result | Comments |
|---|---|---|---|
| 13.1 | The section is derived from the ER Potential Risks & Side Effects section |
🟢 | All six entries are the ER’s own Potential Risks & Side Effects sub-headings. |
| 13.2 | Key variables are [risks_high], [risks_medium], [risks_low], [risks_speculative] | 🟢 | All four spans present and populated (QRS lines 572–583), matching the ER’s 2 / 2 / 1 / 1 tier distribution. |
| 13.3 | Items are as concise as possible. No explanations, no elaborations, no effect sizes, no qualifiers, no attributions, no citations, no study details, no mechanistic explanations, etc. Just the key fact. | 🟢 | Only the ER sub-headings survive; hazard ratios, dose thresholds and mechanism paragraphs are all dropped. |
| 13.4 | Parenthetical content — including frequencies, severity grades, sample notes, mechanistic hints, and example studies — is stripped, NOT preserved. | 🟢 | No parentheses appear in any risks item; the ER’s “⚠️ Conflicted” marker on the cardiovascular risk is also dropped. |
| 13.5 | If no items of a specific sub-section (high, medium, low, speculative) are present the respective <SPAN> is set to “display=none”, not filled with “None documented in human trials to date” or similar empty-state phrasing. |
N/A | All four ER risk tiers contain items, so no span needs hiding. |
14. Monitoring
| # | Description | Result | Comments |
|---|---|---|---|
| 14.1 | The section is derived from the ER Monitoring section |
🟢 | All eight rows come from the ER Monitoring Protocol & Defining Success biomarker table (ER lines 423–432). |
| 14.2 | All measurable/quantifiable biomarkers from the Monitoring section are listed |
🟢 | All eight ER biomarkers present in ER order, with the ER’s optimal ranges and “Why Measure It?” text reproduced faithfully. |
| 14.3 | [monitoring_cadence] is populated with the monitoring cadence/frequency derived from the ER Monitoring section. It is not left with placeholder text or empty. |
🟢 | QRS line 691 condenses the ER’s cadence paragraph: 4–6 weeks, 3–6 months, 12 months then every 12–24 months, plus continuous tolerance tracking during titration. |
15. Qualitative Assessment
| # | Description | Result | Comments |
|---|---|---|---|
| 15.1 | The section is derived from the ER Monitoring section |
🟢 | All five items come from the ER’s “Qualitative markers worth tracking alongside the laboratory values” list (ER lines 436–440). |
| 15.2 | All subjective/qualitative biomarkers from the Monitoring section are listed |
🟢 | All five ER qualitative markers present in ER order, with trailing rationale clauses trimmed. |
Issues 11/08/2026 09:25
Pass rate 100.00%. No issues found.
Issues 11/08/2026 09:18
- 1.2 — “theoretical” qualifier dropped: The ER labels the antiplatelet-supplement interaction “Caution, theoretical.” (ER line 305), but the corresponding item at QRS line 557 (“Supplements with antiplatelet activity (fish oil, garlic, ginkgo, high-dose vitamin E, nattokinase)”) carries no theoretical qualifier, so the one interaction the ER explicitly hedges reads as established.
Fixes 11/08/2026 09:18
- 1.2 — “theoretical” qualifier restored: Appended the ER’s severity qualifier to the antiplatelet-supplement interaction item, changing it from “Supplements with antiplatelet activity (fish oil, garlic, ginkgo, high-dose vitamin E, nattokinase)” to “…nattokinase); theoretical”, matching the ER’s “Caution, theoretical.” labelling at ER line 305.
Issues 11/08/2026 09:08
- 7.2 — At-A-Glance exceeds word cap: The
at_a_glancespan at line 433 runs to 61 words (“A sugar alcohol that tastes like sugar … Lethal to dogs in small amounts.”), one word over the 60-word maximum.
Fixes 11/08/2026 09:08
- 7.2 — At-A-Glance trimmed to 60 words: Changed “the bacteria that cause tooth decay” to “the bacteria behind tooth decay” in the
at_a_glancespan, bringing the summary from 61 words down to the 60-word maximum while preserving the ER’s causal claim.